Alterity Therapeutics Stock Analysis

ATHE Stock  USD 3.94  0.16  4.23%   
Alterity Therapeutics is undervalued with Real Value of 5.06 and Target Price of 9.0. The main objective of Alterity Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Alterity Therapeutics is worth, separate from its market price. There are two main types of Alterity Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Alterity Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Alterity Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

Alterity Stock Analysis Notes

The company recorded a loss per share of 1.51. Alterity Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 9th of January 2023. Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease, Huntington disease, Parkinsons disease, and other neurological disorders in Australia. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Alterity Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. For more info on Alterity Therapeutics please contact the company at 61 3 9349 4906 or go to https://alteritytherapeutics.com.

Alterity Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Alterity Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Alterity Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Alterity Therapeutics is way too risky over 90 days horizon
Alterity Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 4.02 M. Net Loss for the year was (19.12 M) with profit before overhead, payroll, taxes, and interest of 3.54 M.
Alterity Therapeutics currently holds about 34.81 M in cash with (12.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87.
Alterity Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: JPMorgan Chase Acquires Significant Stake in Alterity Therapeutics - TipRanks

Alterity Largest EPS Surprises

Earnings surprises can significantly impact Alterity Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-30
2021-06-30-0.1718-0.13340.038422 
2019-02-28
2018-12-31-0.27-0.00360.266498 
2018-08-31
2018-06-30-0.28-0.00360.276498 
View All Earnings Estimates

Alterity Therapeutics Environmental, Social, and Governance (ESG) Scores

Alterity Therapeutics' ESG score is a quantitative measure that evaluates Alterity Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Alterity Therapeutics' operations that may have significant financial implications and affect Alterity Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Alterity Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Corecap Advisors, Llc2024-09-30
0.0
Note, although Alterity Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Alterity Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.28 M.

Alterity Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.90)(0.94)
Return On Capital Employed(1.63)(1.55)
Return On Assets(1.14)(1.20)
Return On Equity(1.59)(1.51)

Management Efficiency

Alterity Therapeutics has return on total asset (ROA) of (0.7837) % which means that it has lost $0.7837 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5577) %, meaning that it created substantial loss on money invested by shareholders. Alterity Therapeutics' management efficiency ratios could be used to measure how well Alterity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 16, 2025, Return On Tangible Assets is expected to decline to -0.94. The current year's Return On Capital Employed is expected to grow to -1.55. At present, Alterity Therapeutics' Fixed Asset Turnover is projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.20, whereas Total Current Assets are forecasted to decline to about 18.7 M.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(0.27)(0.28)
Price Book Value Ratio 1.19  1.25 
Enterprise Value Multiple(0.27)(0.28)
Price Fair Value 1.19  1.25 
Enterprise Value6.6 M6.3 M
Examining the leadership quality of Alterity Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Operating Margin
(4.70)
Beta
0.479
Return On Assets
(0.78)
Return On Equity
(1.56)

Technical Drivers

As of the 16th of March 2025, Alterity Therapeutics shows the Mean Deviation of 5.78, downside deviation of 5.36, and Risk Adjusted Performance of 0.1271. Alterity Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Alterity Therapeutics treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if Alterity Therapeutics is priced correctly, providing market reflects its regular price of 3.94 per share. Given that Alterity Therapeutics has jensen alpha of 1.43, we suggest you to validate Alterity Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Alterity Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Alterity Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Alterity Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Alterity Therapeutics Outstanding Bonds

Alterity Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alterity Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alterity bonds can be classified according to their maturity, which is the date when Alterity Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Alterity Therapeutics Predictive Daily Indicators

Alterity Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alterity Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Alterity Therapeutics Corporate Filings

6K
14th of March 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
28th of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
24th of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
19th of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
18th of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
10th of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
6th of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
5th of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify

Alterity Therapeutics Forecast Models

Alterity Therapeutics' time-series forecasting models are one of many Alterity Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alterity Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Alterity Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alterity Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alterity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Alterity Therapeutics. By using and applying Alterity Stock analysis, traders can create a robust methodology for identifying Alterity entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(5.46)(5.73)
Operating Profit Margin(5.61)(5.89)
Net Loss(5.47)(5.75)
Gross Profit Margin 1.09  1.03 

Current Alterity Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alterity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alterity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
9.0Strong Buy2Odds
Alterity Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Alterity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Alterity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Alterity Therapeutics, talking to its executives and customers, or listening to Alterity conference calls.
Alterity Analyst Advice Details

Alterity Stock Analysis Indicators

Alterity Therapeutics stock analysis indicators help investors evaluate how Alterity Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alterity Therapeutics shares will generate the highest return on investment. By understating and applying Alterity Therapeutics stock analysis, traders can identify Alterity Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow15.8 M
Total Stockholder Equity13.8 M
Capital Lease Obligations159 K
Property Plant And Equipment Net186.9 K
Cash And Short Term Investments12.6 M
Net Invested Capital13.8 M
Cash12.6 M
50 Day M A3.8326
Net Interest Income268.4 K
Total Current Liabilities5.4 M
Investments-5722.00
Stock Based Compensation882 K
Common Stock Shares Outstanding3.6 B
Tax Provision46.1 K
Free Cash Flow-12.6 M
Operating Income-19.6 M
Other Current Assets2.4 M
Accounts Payable581.1 K
Net Debt-12.5 M
Depreciation147.5 K
Other Operating Expenses23.6 M
Non Current Assets Total186.9 K
Liabilities And Stockholders Equity19.2 M
Home CategoryADR

Complementary Tools for Alterity Stock analysis

When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments